Call for proposals for personalising health and care H2020-PHC-2014-two-stage Closed!


The Framework Programme for Research and Innovation (2014-2020) is implemented by specific programme and work programmes.

The “Societal challenges” responds directly to the policy priorities and societal challenges that are identified in the Europe 2020 strategy and that aim to stimulate the critical mass of research and innovation efforts needed to achieve the Union's policy goals.

The specific objective is to fully exploit the potential of Europe's talent pool and to ensure that the benefits of an innovation-led economy are both maximised and widely distributed across the Union in accordance with the principle of excellence.

Funding shall be focused on the following specific objectives:
(a) Health, demographic change and well-being.
(b) Food security, sustainable agriculture and forestry, marine, maritime and inland water research. and the bioeconomy.
(c) Secure, clean and efficient energy.
(d) Smart, green and integrated transport.
(e) Climate action, environment, resource efficiency and raw materials.
(f) Europe in a changing world - Inclusive, innovative and reflective societies.
(g) Secure societies - Protecting freedom and security of Europe and its citizens.


Actions foreseen within this call for proposals include the following topics:

  • PHC-05-2014: Health promotion and disease prevention: translating 'omics' into stratified approaches. ‘Omics’ research (including but not limited to genomics, epi-genomics, meta-genomics and proteomics) is moving at a breath-taking pace. A major challenge for the next decade is to determine when and how this wealth of ‘omics’ information can be usefully applied by both the public and private sectors for the development of personalised /stratified approaches in health promotion and disease prevention.
  • PHC-06-2014: Evaluating existing screening and prevention programmes. Some existing population based screening and disease prevention programmes have not been assessed for their effectiveness, or vary in terms of their application within and across countries throughout Europe. This may result in inappropriate interventions, delayed provision of the correct treatment, increased disease burden, health inequities and increased costs for health and care systems. Such programmes therefore need systematic evaluation for their impact on health outcomes, cost effectiveness and health equity.
  • PHC-10-2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms. The development of new diagnostics (more sensitive, robust and selective) for improved clinical practice demands the translation of multidisciplinary scientific and technological knowledge from diverse fields into clinical applications. Innovation in this area relies on the development, translation and uptake of existing, new or evolving and often complex technologies. Improved clinical decisions based on new and improved diagnostic tools and techniques should lead to better health outcomes while contributing to the sustainability of the health care system.
  • PHC-17-2014: Comparing the effectiveness of existing healthcare interventions in the elderly. Effective health care for the rapidly growing elderly population in Europe is challenging and complex. This population is subject to frequent and numerous comorbidities, associated poly-pharmacy and impaired hepatic and renal function, as well as problems linked to access to care and compliance. In addition, while the elderly are overrepresented in terms of patient numbers, this group is underrepresented or even excluded from many clinical trials that generate the evidence-base for health care interventions.
  • PHC-23-2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems. Public health, biomedical, social and behavioural research have provided evidence for new approaches to prevention, primary care and treatment. Their integration into health services requires cooperation across sectors and between stakeholders, and challenges the current boundaries of healthcare and established norms of operation. EU Member States have thus far had different responses to the need for reform, presenting an opportunity to learn how best to react to preserve and promote population health, mitigate the effects of the economic crisis and avoid increases in health inequalities.
  • PHC-01-2014: Understanding health, ageing and disease: determinants, risk factors and pathways. The development and preservation of good health, and the occurrence and evolution of common diseases and disabilities result from varying degrees of interaction between the genetic make-up of individual human beings and behavioural, environmental (including endocrine disruptors), occupational, nutritional and other modifiable lifestyle factors. This applies from the earliest stages of development throughout life. Understanding these factors, their interactions and the extent to which they contribute to health preservation and/or to disease development is important for the development of preventive and therapeutic measures supporting good health, prolonged active independence and a productive working life, not least in the context of changing demographic patterns and the ageing of the European population. In particular, proposals should contribute to improving risk identification and validation, and will allow better diagnosis, risk-based prevention strategies and policies.
  • PHC-13-2014: New therapies for chronic non-communicable diseases. Chronic non-communicable diseases represent a significant burden on individuals and healthcare systems. Innovative, cost effective therapeutic approaches are required to provide the best quality of care when prevention fails. While a considerable amount of knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.
  • PHC-32-2014: Advancing bioinformatics to meet biomedical and clinical needs. Recent technological advances in molecular biology, biomedical sciences and systems biology have enabled a greatly increased rate of data generation and the production of many different types of data. Furthermore, these new technologies are gradually becoming much less expensive and more accessible to individual laboratories and clinics. The rate of data generation at a local level is therefore set to increase dramatically. Currently available bioinformatics tools are however insufficient to maximise the use of these new, diverse and complex data. Deficiencies exist in data collection, storage, organisation, integration, analysis and exploitation is therefore not optimal. Network bioinformatics requires support in Europe in order to maintain scientific competitiveness.

European community funding

The Community provisional funding available for the call for proposals is:

  • 303,00 Million EUR (Global Budget)

All the important deadlines

  • 11 March 2014 - 7 years ago (Deadline for the presentation of proposals)

Further information about the call

Official webpage of the call

Useful documents

  • Personalising health and care (Legal base)

Organisations eligible to participate

Opened to the following bodies or institutes with legal status established in the covered areas:

  • Any legal organisation

Covered areas

Bodies or institutes must have their registered legal seat in one of the countries taking part in the Programme which are:

  • European Union (EU)

Directorate-Generale responsible

Directorate-General for Research

Related calls for proposals

Related calls

Explore other programmes